MedImmune, the R&D department of pharma giant AstraZeneca, has licensed the rights to develop and test cancer-fighting drugs to Yale spin-out Koltan Pharmaceuticals.
Spun out of the University’s School of Medicine in 2007, the US-based life sciences firm Koltan intends to develop the drug, which has been designed to target a receptor connected to cancers include breast, ovary, colon and lung.
Both companies will have the potential for future cost, risk and profit sharing for the product, which should commence…
